193 related articles for article (PubMed ID: 3116080)
21. Human interleukin 7 is a B cell growth factor for activated B cells.
Joshi PC; Choi YS
Eur J Immunol; 1991 Mar; 21(3):681-6. PubMed ID: 1826263
[TBL] [Abstract][Full Text] [Related]
22. Regulatory effects of IL-4 on human B-cell response to IL-2.
Galanaud P; Karray S; Llorente L
Eur Cytokine Netw; 1990; 1(2):57-64. PubMed ID: 2102812
[TBL] [Abstract][Full Text] [Related]
23. Sequential requirements for cell cycle progression of resting human B cells after activation by anti-Ig.
Muraguchi A; Kehrl JH; Butler JL; Fauci AS
J Immunol; 1984 Jan; 132(1):176-80. PubMed ID: 6197443
[TBL] [Abstract][Full Text] [Related]
24. Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells.
Smeland EB; Beiske K; Ohlsson R; Holte H; Ruud E; Blomhoff HK; Jefferis R; Godal T
J Immunol; 1987 May; 138(10):3179-84. PubMed ID: 3553323
[TBL] [Abstract][Full Text] [Related]
25. Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor.
Gordon J; Webb AJ; Walker L; Guy GR; Rowe M
Eur J Immunol; 1986 Dec; 16(12):1627-30. PubMed ID: 3028819
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2.
Hivroz C; Grillot-Courvalin C; Brouet JC; Seligmann M
Eur J Immunol; 1986 Aug; 16(8):1001-4. PubMed ID: 3488907
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).
Ledbetter JA; Shu G; Gallagher M; Clark EA
J Immunol; 1987 Feb; 138(3):788-94. PubMed ID: 3492534
[TBL] [Abstract][Full Text] [Related]
28. Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro.
Ferro LM; Zola H
Immunology; 1990 Mar; 69(3):373-8. PubMed ID: 2138127
[TBL] [Abstract][Full Text] [Related]
29. Characterization of human B cell growth factor (BCGF) from cloned T cells or mitogen-stimulated T cells.
Yoshizaki K; Nakagawa T; Fukunaga K; Kaieda T; Maruyama S; Kishimoto S; Yamamura Y; Kishimoto T
J Immunol; 1983 Mar; 130(3):1241-6. PubMed ID: 6600479
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory influence of IL-4 on human B cell responsiveness.
Jelinek DF; Lipsky PE
J Immunol; 1988 Jul; 141(1):164-73. PubMed ID: 2837507
[TBL] [Abstract][Full Text] [Related]
31. B cell hyperactivity in systemic lupus erythematosus: selectively enhanced responsiveness to a high molecular weight B cell growth factor.
Delfraissy JF; Wallon C; Vazquez A; Dugas B; Dormont J; Galanaud P
Eur J Immunol; 1986 Oct; 16(10):1251-6. PubMed ID: 3095124
[TBL] [Abstract][Full Text] [Related]
32. Requirements of a costimulus for IL-4-induced IgE class switching in murine B cells activated via antigen receptors: effectiveness of 8-mercaptoguanosine.
Hikida M; Takai T; Ohmori H
J Immunol; 1996 Apr; 156(8):2730-6. PubMed ID: 8609390
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of a B cell growth inhibitory factor (BIF) on BCGF-dependent B cell proliferation.
Kawano M; Iwato K; Kuramoto A
J Immunol; 1985 Jan; 134(1):375-81. PubMed ID: 3871108
[TBL] [Abstract][Full Text] [Related]
34. Identification of a receptor for high molecular weight human B cell growth factor.
Ambrus JL; Jurgensen CH; Brown EJ; McFarland P; Fauci AS
J Immunol; 1988 Aug; 141(3):861-9. PubMed ID: 3260914
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD5 extends the proliferative response of human CD5+ B cells activated with anti-IgM and interleukin-2.
Jamin C; Le Corre R; Lydyard PM; Youinou P
Eur J Immunol; 1996 Jan; 26(1):57-62. PubMed ID: 8566084
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-12 stimulates B cell growth by inducing IFN-gamma.
Li L; Young D; Wolf SF; Choi YS
Cell Immunol; 1996 Mar; 168(2):133-40. PubMed ID: 8640858
[TBL] [Abstract][Full Text] [Related]
37. Low molecular weight B cell growth factor-responsive cloned human B cell lines. I. Phenotypic differences and lack of requirement for CD23 (Fc epsilon RII).
Warrington RJ; Rutherford WJ; Wong SK; Cook JM; Rector ES
J Immunol; 1989 Oct; 143(8):2546-52. PubMed ID: 2529311
[TBL] [Abstract][Full Text] [Related]
38. Activation of the phosphatidylinositol metabolic pathway by low molecular weight B cell growth factor.
Renard D; Petit-Koskas E; Génot E; Dugas B; Poggioli J; Kolb JP
Eur J Immunol; 1988 Nov; 18(11):1705-11. PubMed ID: 2849549
[TBL] [Abstract][Full Text] [Related]
39. In vitro effects of B cell growth and maturation factor on B-CLL lymphocytes.
Karray S; Emilie D; Galanaud P
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):275-8. PubMed ID: 3065728
[TBL] [Abstract][Full Text] [Related]
40. Characterization of B cell growth in systemic lupus erythematosus. Effects of recombinant 12-kDa B cell growth factor, interleukin 4 and transforming growth factor-beta.
Flescher E; Fossum D; Ballester A; Maizel A; Sharma S; Talal N
Eur J Immunol; 1990 Nov; 20(11):2425-30. PubMed ID: 2253682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
